

1. **SSRIs are approved for 1st line treatment of OCD (Fluoxetine).** BZO's are not first line treatment for OCD. Stahl

p. 575

2. The primary action of hallucinogenic drugs such as LSD, mescaline, psilocybin, and MDMA are agonism of 5HT_{2A} receptors. Hallucinogens may have additional actions at other serotonin receptors (particularly 5HT_{1A} and 5HT_{2C}) and at other neurotransmitter systems, and MDMA in particular also blocks the serotonin transporter (SERT). Stahl p. 562- Figure 14-19.

Mechanism of hallucinogens at 5HT_{2A} receptors

3. **The hypothalamus serves as the brain center that controls appetite by utilizing a complex set of circuits and regulators.** One formulation of how the hypothalamus does this is the notion that there is a major appetite-stimulating pathway whose actions are mediated by two peptides (neuropeptide Y and agouti-related protein).. Stahl p.564-566

4. Appetite is regulated by the balance between an appetite-stimulating pathway (on the left) that releases agouti-related peptide (AgRP) and neuropeptide Y (NPY), and an appetite-suppressing pathway (on the right) that releases α -melanocyte-stimulating hormone (α -MSH). Stahl p.564- 566.

5. Weight gain can occur either by excessive activity of the appetite-stimulating pathway, by deficient activity of the appetite-suppressing pathway, or both. Stahl p.564-566.

6. Phentermine acts much like amphetamine, blocking both the dopamine transporter (DAT) and the norepinephrine transporter (NET) and, at high doses, the vesicular monoamine transporter (VMAT). Stahl p.573 Chapter 14